Baylor Scott & White Charles A. Sammons Cancer Center – Dallas and Baylor Scott & White T. Boone Pickens Cancer Hospital make up one of the largest cancer treatment centers in the U.S. As a destination cancer center in immunotherapy and backed by the resources of Texas’ largest not-for-profit healthcare system, we offer innovative, comprehensive and personalized cancer care plans tailored to each patient’s unique needs. From highly specialized programs based on type of cancer to forward-thinking clinical trials to a holistic approach to healing, we are with our patients along every step of their journey no matter how challenging the road becomes.
O’Shaughnessy Showcases Highlights in Breast Cancer Guiding 2023 IBC Congresses
April 21st 2023Joyce A. O’Shaughnessy, MD, highlights multidisciplinary approaches including discussions on tumor boards, and discusses how to better assist patients with accessing care, and notable advances in the field particularly with the HER2 classification.
Dr Christensen on the Influence of Patient Selection for BCL-2 Inhibitor Treatment in AML
April 14th 2023Bradley W. Christensen, MD, discusses the process of patient selection for BCL-2 induction therapy in patients with acute myeloid leukemia in accordance with their individual disease characteristics.
A Wealth of Clinical Trials Expands Potential Breast Cancer Treatment Options
January 26th 2023Joyce O’Shaughnessy, MD, highlights key data from the 2022 San Antonio Breast Cancer Symposium, explains how trastuzumab deruxtecan and CDK4/6 inhibitors are altering the treatment landscape, and discusses novel data on steroid receptor expression in triple-negative breast cancer.
Dr. O'Shaughnessy on Key Results From the EMERALD Trial in HR+/HER2- Breast Cancer
January 18th 2023Joyce A. O’Shaughnessy, MD, discusses key results from the phase 3 EMERALD trial of elacestrant, and the potential effects of the agent’s approval on the use of oral selective estrogen receptor degraders for hormone receptor–positive, HER2-negative breast cancer.
EU Panel Recommends Adjuvant Nivolumab for Select Esophageal, GEJ Cancers
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction cancer who have residual pathologic disease after previous neoadjuvant chemoradiotherapy.